At a glance
ClinicalIndex Comparison Record- ✓Age 6 to 18 years inclusive
- ✓Diagnosis of non-infectious uveitis associated with JIA requiring high-frequency anti-inflammatory treatment (≥3 times daily)
- ✓Active uveitis on current regimen with anterior chamber cell grade ≥1+ in at least one eye
- ✓Visual acuity ≥20/640 (logMAR <1.54) in at least one eye
- ✕Prior treatment with IL-2-directed monoclonal antibody or other investigational agents that would interfere with daclizumab evaluation
- ✕History or diagnosis of Behçet's disease
- ✕Significant active infection or history of recurring serious infections
- ✕History of cancer (other than non-melanoma skin cancer) within past 5 years
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab)
In Brief
A Phase 2 clinical trial evaluating Daclizumab for Anterior Uveitis and 3 related conditions. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study will examine the safety and effectiveness of a monoclonal antibody called humanized anti-Tac (HAT, also called daclizumab) to treat children and adolescents with uveitis (chronic inflammatory eye disease) associated with juvenile idiopathic arthritis (JIA). Monoclonal antibodies are genetically engineered proteins made in large quantities and directed against a specific target in the body. The HAT antibody is designed to prevent a specific chemical interaction needed for immune cells to produce inflammation. Current treatments for uveitis include steroids and immune-suppressing drugs. These treatments do not always work or they may cause significant side effects. This study will determine whether daclizumab can improve uveitis in children and reduce the need for other medicines. Patients between 6 and 18 years of age with active non-infectious JIA-associated uveitis requiring treatment with anti-inflammatory medications as often as three times a day or more may be eligible for this study. Each candidate is screened with a medical history, physical examination, blood tests, eye examination, and the following specialized tests: * Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating the presence of inflammation. * Optical coherence tomography to measure retinal thickness. The eyes are examined through a machine that produces cross-sectional pictures of the retina. These measures are repeated during the study to determine changes, if any, in retinal thickening. * Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to examine and photograph the back of the eye. Upon entering the study, participants receive a 90-minute infusion of daclizumab through a catheter (plastic tube) placed in an arm vein. They return to the clinic after 14 days and again after 28 days for repeat eye examinations, blood tests, and daclizumab infusions. Four weeks after the third infusion, patients are examined for response to treatment. Those who have benefited from daclizumab may continue receiving monthly infusions of the drug for up to one year. A blood test and eye examination are done at the time of each infusion. Patients whose disease has remained active 12 weeks after the first infusion are taken off the study and treated with other medications.